• Legislative Information

  • Advocacy-gavel.jpg

  • BioUtah Joins AdvaMed in Support for H.R. 5009

    H.R. 5009 would provide temporary transitional Medicare coverage for FDA approved or cleared breakthrough products, using an accelerated coding process. Removing delays and uncertainties from the process for coverage and reimbursement of products that truly represent significant clinical advances will be an important stimulus to investment in and development of these breakthrough diagnostics and treatments. 

    The bill would also make important changes to the New Technology Add-On Payment and outpatient pass-through programs. These improvements are designed to reduce coverage and payment disincentives that limit prompt patient access to innovative but more costly technologies.

    Download Letters Here:

    House Breakthrough State Association Letter

    Senate Breakthrough State Association Letter

  • BioUtah's Comment Letter to GOED about Technology Commercialization and Innovation Program (TCIP)